Prestige BioPharma Limited
Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
950210 | KO
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Singapore
- Address:
- 21 BIOPOLIS ROAD #04-24 NUCLEOS, SINGAPORE
- Website:
- https://prestigebiopharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Prestige BioPharma Limited is a biopharmaceutical company specializing in the development of biosimilars and innovative, first-in-class antibody drugs. The company pursues a dual-track strategy focused on both creating affordable, high-quality biosimilars to enhance patient access and discovering novel therapeutics and vaccines for life-threatening diseases. Its operations cover the full development lifecycle, from discovery and research to clinical development, registration, and commercialization. Prestige BioPharma aims to become a global innovation hub by fostering collaboration and advancing biopharmaceutical technologies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-19 00:00 |
Audit Report / Information
감사보고서제출
|
Korean | 21.8 KB | ||
| 2025-09-19 00:00 |
Annual Report
사업보고서 (2025.06)
|
Korean | 3.7 MB | ||
| 2025-09-16 00:00 |
Regulatory News Service
[기재정정]단일판매ㆍ공급계약체결
|
Korean | 12.8 KB | ||
| 2025-09-11 00:00 |
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의
|
Korean | 17.3 KB | ||
| 2025-09-11 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 136.7 KB | ||
| 2025-09-09 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 9.5 KB | ||
| 2025-08-18 00:00 |
Regulatory News Service
단일판매ㆍ공급계약체결
|
Korean | 8.6 KB | ||
| 2025-08-13 00:00 |
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변경
|
Korean | 19.1 KB | ||
| 2025-07-31 00:00 |
Regulatory News Service
[기재정정]투자판단관련주요경영사항 (특허권 취득)
|
Korean | 15.7 KB | ||
| 2025-06-13 00:00 |
Pre-Annual General Meeting Information
기타경영사항(자율공시) (제10기 정기주주총회 권리주주 확정을 위한 증권예탁증권 기준일 설정 공고)
|
Korean | 4.4 KB | ||
| 2025-05-30 00:00 |
Governance Information
기업지배구조보고서공시
|
Korean | 934.4 KB | ||
| 2025-05-30 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.6 MB | ||
| 2025-05-26 00:00 |
M&A Activity
투자판단관련주요경영사항 (Tuznue (HD201,Trastuzumab 바이오시밀러) 판매에 대한 라이선스 및 공급 계…
|
Korean | 8.9 KB | ||
| 2025-02-28 00:00 |
Interim Report
반기보고서 (2024.12)
|
Korean | 1.5 MB | ||
| 2025-02-13 00:00 |
Regulatory News Service
주식등의대량보유상황보고서(약식)
|
Korean | 72.7 KB |
Automate Your Workflow. Get a real-time feed of all Prestige BioPharma Limited filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Prestige BioPharma Limited via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
